Haverford Trust Co Makes New $486,000 Investment in Gilead Sciences, Inc. $GILD

Haverford Trust Co acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,847 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

Other large investors also recently modified their holdings of the company. Paulson Wealth Management Inc. raised its holdings in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares during the period. Essex Financial Services Inc. boosted its holdings in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. grew its position in shares of Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the last quarter. Alpha Cubed Investments LLC grew its position in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Finally, Financial Connections Group Inc. increased its stake in shares of Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on GILD shares. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Morgan Stanley decreased their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Finally, Truist Financial lowered their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 87,000 shares of company stock valued at $11,562,960. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $146.12 on Monday. The firm has a market cap of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock’s fifty day moving average price is $131.97 and its two-hundred day moving average price is $136.55. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company’s revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.01 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.